Journal ArticleDOI
A rating scale for extrapyramidal side effects
Reads0
Chats0
TLDR
A modification of an earlier rating scale for extrapyramidal system disturbance is described, and evidence for the validity and reliability of the scale is presented.Abstract:
SUMMARY
A modification of an earlier rating scale for extrapyramidal system disturbance is described, and evidence for the validity and reliability of the scale is presented. The usefulness of the scale in studies of neuroleptic drugs is discussed. By its application it is possible to quantify extrapyramidal side effects and to separate them into four principal factors.read more
Citations
More filters
Journal ArticleDOI
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.
TL;DR: The efficacy and tolerability profile of haloperidol (including its propensity for EPS) supported study validity and quetiapine was effective and well tolerated.
Journal ArticleDOI
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.
TL;DR: People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared to the Non-depressed, and their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions.
Journal ArticleDOI
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
Gary S. Sachs,Raymond Sanchez,Ronald N. Marcus,Elyse Stock,Robert D. McQuade,William H. Carson,Neveen Abou-Gharbia,Cheryl Impellizzeri,Stephen Kaplita,Linda Rollin,Taro Iwamoto +10 more
TL;DR: Aripiprazole demonstrated superior efficacy to placebo in the treatment of patients with bipolar I disorder presenting with acute manic or mixed episodes, and exhibited a favourable safety and tolerability profile.
Journal ArticleDOI
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
Thomas H. McGlashan,Robert B. Zipursky,Diana O. Perkins,Jean Addington,Tandy J. Miller,Scott W. Woods,Keith A. Hawkins,Ralph E. Hoffman,Stacy R. Lindborg,Mauricio Tohen,Alan Breier +10 more
TL;DR: The first double-blind placebo-controlled clinical trial of an atypical neuroleptic medication is being conducted in symptomatic treatment-seeking patients meeting new diagnostic criteria for a putative prodromal syndrome, identifying them as being at high risk for developing psychosis in the near future.
Journal ArticleDOI
Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review
Philip E. Lee,Sudeep S. Gill,Morris Freedman,Susan E. Bronskill,Michael P. Hillmer,Paula A. Rochon +5 more
TL;DR: Limited evidence supports the perception of improved efficacy and adverse event profiles compared with typical antipsychotic drugs in the management of the behavioural and psychological symptoms of dementia.
References
More filters
Journal Article
Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance.
Simpson Gm,Kunz-Bartholini E +1 more
Journal Article
Pharmacologically induced Parkinson-like signs as index of the therapeutic potential.
Journal ArticleDOI
The Action of Neuroleptic Drugs.
TL;DR: The major portion of this monograph consists of a restatement by the senior author of his concepts regarding the modus operandi and therapeutic use of the neuroleptic drugs in clinical psychiatry.